Karyopharm Therapeutics Inc.
Develops novel oral cancer therapies by inhibiting nuclear export for hard-to-treat tumors.
KPTI | NDAQ
Overview
Corporate Details
- ISIN(s):
- US48576U2050
- LEI:
- Country:
- United States of America
- Address:
- 85 WELLS AVENUE, 2459 NEWTON
- Website:
- https://karyopharm.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel cancer therapies. The company pioneers first-in-class medicines by targeting nuclear export inhibition to treat various cancers, particularly hematologic malignancies and solid tumors. Its lead asset is XPOVIO® (selinexor), an oral Selective Inhibitor of Nuclear Export (SINE) compound. Karyopharm's pipeline is dedicated to addressing diseases with high unmet medical needs through innovative scientific approaches.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Karyopharm Therapeutics Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Karyopharm Therapeutics Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Karyopharm Therapeutics Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
/other/Diamyd_Medical_AB_publ-logo.png){kind=logo}
